This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
BERLIN: Pfizer-Biontech's coronavirus vaccine offers more protection than earlier thought with effectiveness in preventing symptomatic disease reaching 97 percent, according to real world evidence published Thursday by pharma companies.
Using data from January 17 to March 6 from Israel's national vaccination campaign, Pfizer-Biontech found that prevention against asymptomatic disease also reached 94 percent.
An earlier real world study had showed effectiveness at preventing symptomatic disease at 94 percent and asymptomatic illness at 92 percent.
Read More